Amyloidosis; Systemic
8
3
4
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
12.5%
1 terminated out of 8 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
A Study of AT-02 in Subjects With Systemic Amyloidosis.
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
Essen Amyloidosis Registry
Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis
Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients
A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis
Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis
BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients